Characterization and comparative performance of lentiviral vector preparations concentrated by either one-step ultrafiltration or ultracentrifugation

Virus Research

Volumn 175, Issue 1, 2013, Pages 1-11

  Papanikolaou, Eleni ^a,b   Kontostathi, Georgia ^a   Drakopoulou, Ekati ^a,b   Georgomanoli, Maria ^a,b   Stamateris, Evangelos ^a,b   Vougas, Kostas ^a   Vlahou, Antonia ^a   Maloy, Andrew ^c   Ware, Mark ^c   Anagnou, Nicholas P ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c MALVERN INSTRUMENTS LTD   (United Kingdom)

Author keywords

Apoptosis; CD34+ hematopoietic stem cells; Gene therapy; Lentiviral vectors; Mouse bone marrow cells; Ultrafiltration

Indexed keywords

LENTIVIRUS VECTOR;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; LENTIVIRINAE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ULTRACENTRIFUGATION; ULTRAFILTRATION; VIRUS PARTICLE; VIRUS TITRATION;

ANIMALS; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; MICE; MICE, INBRED C57BL; PEPTIDE MAPPING; TRANSDUCTION, GENETIC; ULTRACENTRIFUGATION; ULTRAFILTRATION; VIROLOGY;

MURINAE; VESICULAR STOMATITIS VIRUS;

EID: 84878478390     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.03.015     Document Type: Article

References (31)

1. Ako-Adjei D., Johnson M.C., Vogt V.M. The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into virus-like particles. Journal of Virology 2005, 79:13463-13472.
2. Anderson N.L., Anderson N.G. High resolution two-dimensional electrophoresis of human plasma proteins. Proceedings of the National Academy of Sciences of the United States of America 1977, 74:5421-5425.
3. Burns J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:8033-8037.
4. Carmo M., Faria T.Q., Falk H., Coroadinha A.S., Teixeira M., Merten O.W., Gény-Fiamma C., Alves P.M., Danos O., Panet A., Carrondo M.J., Cruz P.E. Relationship between retroviral vector membrane and vector stability. Journal of General Virology 2006, 87:1349-1356.
5. Carr R., Hole P., Malloy A. Sizing of nanoparticles by visualising and simultaneously tracking the Brownian motion of nanoparticles separately within a suspension. 8th International Congress on Optical Particle Characterisation 2007, 25.
6. Cavazzana-Calvo M., Payen E., Negre O., Wang G., Hehir K., Fusil F., Down J., Denaro M., Brady T., Westerman K., Cavallesco R., Gillet-Legrand B., Caccavelli L., Sgarra R., Maouche-Chrétien L., Bernaudin F., Girot R., Dorazio R., Mulder G.J., Polack A., Bank A., Soulier J., Larghero J., Kabbara N., Dalle B., Gourme l B., Socie G., Chrétien S., Cartier N., Aubourg P., Fischer A., Cornetta K., Galacteros F., Beuzard Y., Gluckman E., Bushman F., Hacein-Bey-Abina S., Leboulch P. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010, 467:318-323.
7. Coleman J.E., Huentelman M.J., Kasparov S., Metcalfe B.L., Paton J.F., Katovich M.J., Semple-Rowland S.L., Raizada M.K. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiological Genomics 2003, 12:221-228.
8. Cui Y., Golob J., Kelleher E., Ye Z., Pardoll D., Cheng L. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 2002, 99:399-408.
9. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. Journal of Virology 1998, 72:8463-8471.
10. Ettinger W.H., Flotte T.R. The role of gene and cell therapy in the era of health care reform. Human Gene Therapy 2011, 22:1307-1309.
11. Fountoulakis M., Tsangaris G., Oh J.E., Maris A., Lubec G. Protein profile of the HeLa cell line. Journal of Chromatography A 2004, 1038:247-265.
12. Galipeau J., Li H., Paquin A., Sicilia F., Karpati G., Nalbantoglu J. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Research 1999, 59:2384-2394.
13. Geraerts M., Willems S., Baekelandt V., Debyser Z., Gijsbers R. Comparison of lentiviral vector titration methods. BMC Biotechnology 2006, 6:34-44.
14. Hanawa H., Kelly P.F., Nathwani A.C., Persons D.A., Vandergriff J.A., Hargrove P., Vanin E.F., Nienhuis A.W. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Molecular Therapy 2002, 5:242-251.
15. Kutner R.H., Zhang X.Y., Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nature Protocols 2009, 4:495-505.
16. Logan A.C., Nightingale S.J., Haas D.L., Cho G.J., Pepper K.A., Kohn D.B. Factors influencing the titer and infectivity of lentiviral vectors. Human Gene Therapy 2004, 15:976-988.
17. Mathias L.A., Fisher T.C., Zeng L., Meiselman H.J., Weinberg K.I., Hiti A.L., Malik P. Ineffective erythropoiesis in β-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Experimental Hematology 2000, 28:1343-1353.
18. Millington M., Arndt A., Boyd M., Applegate T., Shen S. Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells. PLoS ONE 2009, 4:e6461.
19. Papanikolaou E., Anagnou N.P. Major challenges for gene therapy of thalassemia and sickle cell disease. Current Gene Therapy 2010, 5:404-412.
20. Papanikolaou E., Georgomanoli M., Stamateris E., Panetsos F., Karagiorga M., Tsaftaridis P., Graphakos S., Anagnou N.P. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells. Human Gene Therapy 2012, 23:15-31.
21. Reiser J., Harmison G., Kluepfel-Stahl S., Brady R.O., Karlsson S., Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:15266-15271.
22. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Therapy 2000, 7:910-913.
23. Sena-Esteves M., Tebbets J.C., Steffens S., Crombleholme T., Flake A.W. Optimized large-scale production of high titer lentivirus vector pseudotypes. Journal of Virological Methods 2004, 122:131-139.
24. Segura M.M., Garnier A., Kamen A. Purification and characterization of retrovirus vector particles by rate zonal ultracentrifugation. Journal of Virological Methods 2006, 133:82-91.
25. Segura M.M., Garnier A., Di Falco M.R., Whissell G., Meneses-Acosta A., Arcand N., Kamen A. Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. Journal of Virology 2008, 82:1107-1117.
26. Segura M.M., Kamen A.A., Garnier A. Overview of current scalable methods for purification of viral vectors. Viral Vectors for Gene Therapy 2011, 89-116. Humana Press. O.-W. Merten, M. Al-Rubeai (Eds.).
27. Shaw A., Bischof D., Jasti A., Ernstberger A., Hawkins T., Cornetta K. Using pulmozyme DNase treatment in lentiviral vector production. Human Gene Therapy Methods 2012, 23:65-71.
28. Tiscornia G., Singer O., Verma I.M. Production and purification of lentiviral vectors. Nature Protocols 2006, 1:241-245.
29. + cells following lentiviral vector-mediated gene transfer. Blood 2011, 117:2817-2826.
30. Zimmermann K., Scheibe O., Kocourek A., Muelich J., Jurkiewicz E., Pfeifer A. Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltration. BMC Biotechnology 2011, 11:55.
31. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. Journal of Virology 1998, 72:9873-9880.